BioSpace News Archive

The additional 2025 notes will be issued under the indenture dated October 10, 2017 that governs Hologic’s 4.375% senior notes due 2025.

Constellation Pharmaceuticals announced it has initiated a Phase 1b/2 clinical trial to evaluate CPI-1205, a small-molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2).

Ophthotech announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), complement C5 inhibitor, in patients with autosomal recessive Stargardt disease (STGD1).

Tenax announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.

Novoheart announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models.

CompleWare and YPrime announce a partnership agreement to deliver enhanced service offerings involving clinical trials, eCOA technology and IRT.

Dr. Jeffs brings over 25 years of biopharmaceutical industry experience, including 18 years at United Therapeutics where he retired in 2016 as President and Co-CEO.

The Millar catheter provides an easier way to measure pressures in these patients due to its reduced size and signal accuracy.

Under the terms of the agreement, ShangPharma Innovation will provide funding and preclinical research support to further ISMMS’s objectives of validating drug targets and establishing programs to discover new therapies.